Therefore, our findings establish that specific targeting of PPARγ, CB2 and HIF pathway with VCE-004.8 could represent a potential therapeutic approach to obesity and T2D, without the harmful effects on adipogenesis and osteoblastogenesis associated with PPARγ full agonists. The gene discussed is CNR2; the disease is obesity due to melanocortin 4 receptor deficiency.